• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

Hypoxia: The Cornerstone of Glioblastoma

27 de November de 2021
Int J Mol Sci. 2021 Nov 22;22(22):12608. doi: 10.3390/ijms222212608.ABSTRACTGlioblastoma…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-11-27 11:00:002021-11-27 11:00:00Hypoxia: The Cornerstone of Glioblastoma

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance

12 de November de 2021
Front Oncol. 2021 Oct 26;11:764506. doi: 10.3389/fonc.2021.764506.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-11-12 11:00:002021-11-12 11:00:00Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance

Curcumin: A therapeutic strategy for colorectal cancer?

17 de September de 2020
Semin Cancer Biol. 2021 Aug;73:321-330. doi: 10.1016/j.semcancer.2020.09.004.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2020-09-17 10:00:002020-09-17 10:00:00Curcumin: A therapeutic strategy for colorectal cancer?

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

17 de October de 2019
Cancers (Basel). 2019 Oct 11;11(10):1540. doi: 10.3390/cancers11101540.ABSTRACTIn…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-17 10:00:002019-10-17 10:00:00Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

28 de November de 2018
World J Gastroenterol. 2018 Nov 14;24(42):4738-4749. doi: 10.3748/wjg.v24.i42.4738.ABSTRACTColorectal…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-11-28 11:00:002018-11-28 11:00:00CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

24 de October de 2018
Int J Mol Sci. 2018 Oct 19;19(10):3249. doi: 10.3390/ijms19103249.ABSTRACTHomologous…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-10-24 10:00:002018-10-24 10:00:00Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

18 de November de 2017
Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-11-18 11:00:002017-11-18 11:00:00Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

11 de November de 2017
Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-11-11 11:00:002017-11-11 11:00:00Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

3 de November de 2016
Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467.NO ABSTRACTPMID:27804975…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-11-03 10:00:002016-11-03 10:00:00Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer

14 de August de 2016
Gastroenterology. 2016 Nov;151(5):961-972. doi: 10.1053/j.gastro.2016.08.001.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-08-14 10:00:002016-08-14 10:00:00Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer

Resistant mechanisms to BRAF inhibitors in melanoma

19 de July de 2016
Ann Transl Med. 2016 Jun;4(12):237. doi: 10.21037/atm.2016.06.07.ABSTRACTPatients…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-07-19 10:00:002016-07-19 10:00:00Resistant mechanisms to BRAF inhibitors in melanoma

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

20 de April de 2016
Sci Rep. 2016 Apr 19;6:24675. doi: 10.1038/srep24675.ABSTRACTResistance…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-04-20 10:00:002016-04-20 10:00:00Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
Page 2 of 41234

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}